novartis ag

 

  • [6] Type: Public (Aktiengesellschaft); Traded as: SIX: NOVN, NYSE: NVS; ISIN: CH0012005267; Industry: Pharmaceuticals; Predecessors: Ciba-Geigy, Sandoz (via merger); Founded:
    March 1996; 26 years ago (from merger) ; Founders: Johann Rudolf, Alexander Clavel ; Headquarters: Basel, Switzerland, 47.5744252°N 7.5764914°E, Cambridge, Massachusetts, United States; Area served: Worldwide; Key people: Vasant Narasimhan
    (CEO); Products: Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list…); Revenue: US$51.63 billion (2021)[3]; Operating income: US$11.69 billion (2021)[3]; ; Net income:
    US$24.02 billion (2021)[3] ; Total assets: US$131.79 billion (2021)[3] ; Total equity: US$67.82 billion (2021)[3] ; Number of employees: 110,000 (2021)[3] Corporate structure Novartis AG is a publicly traded Swiss holding company that operates
    through the Novartis Group.

  • [12]: 150 [13] Novartis operates directly through subsidiaries, each of which fall under one of the divisions, and that Novartis categorizes as fulfilling one or more of the
    following functions: Holding/Finance, Sales, Production, and Research[8][12]: 251–253  Novartis AG also held 33.3 percent of the shares of Roche until 2022, however it did not exercise control over Roche.

  • [108] In August 2022, the company announced its plan to spin off Sandoz generic drugs unit to form a publicly traded business as part of a restructuring.

  • [87] In August 2018, Novartis signed a deal with Laekna-a Shanghai-based pharmaceutical company for its two clinical-stage cancer drugs.

  • [101][102] In October 2020, as part of a joint venture to develop therapeutic drugs to combat COVID-19, Novartis bought 6% of all shares outstanding in Swiss DARPin research
    company Molecular Partners AG at CHF 23 per share.

  • [53] In 2005, Novartis expanded its subsidiary Sandoz significantly through the US$8.29 billion acquisition of Hexal, one of Germany’s leading generic drug companies, and
    Eon Labs, a fast-growing United States generic pharmaceutical company.

  • [71] In April 2014, Novartis announced that it would acquire GlaxoSmithKline’s cancer drug business for $16 billion as well as selling its vaccines business to GlaxoSmithKline
    for $7.1 billion.

  • [92] In late December the company announced it would acquire France-based contract manufacturer, CellforCure from LFB, boosting its capacity to produce cell and gene therapies.

  • [64] Also in 2012, Novartis became the biggest manufacturer of generic skin care medicine, after agreeing to buy Fougera Pharmaceuticals for $1.525 billion in cash.

  • [11] With the unit having generated US$9.69 billion in 2021, the spin-off would create the biggest generic drugs company in Europe by sales.

  • [100] In October Novartis announced it would acquire Vedere Bio for $280 million boosting the businesses cell and gene therapy offerings.

  • [57] In 2009, Novartis reached an agreement to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic
    initiative to build a vaccines industry leader in this country and expand the group’s limited presence in this fast-growing market segment.

  • [129] In April 2014, Novartis divested its consumer health section with $3,5 billion worth of assets into a new joint venture with GlaxoSmithKline, named GSK Consumer Healthcare,
    of which Novartis will hold a 36,5% stake.

  • [95] In late November 2019, the business announced it would acquire The Medicines Company for US$9.7 billion ($85 per share) in order to acquire amongst other assets, the
    cholesterol lowering therapy; inclisiran.

  • [104][105] In September 2021, the company announced it would acquire gene-therapy business, Arctos Medical, broadening its optogenetics range.

  • The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.

  • [73] In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL
    for $275 million.

  • [72] In August 2014 Genetic Engineering & Biotechnology News reported that Novartis had acquired a 15 percent stake in Gamida Cell for $35 million, with the option to purchase
    the whole company for approximately $165 million.

  • [99] Also in September, BioNTech has leased a large production facility from Novartis to follow all advance demands for its coronavirus vaccine in Europe and sell it to China.

  • [80] In November 2016, the company announced it would acquire Selexys Pharmaceuticals for $665 million.

  • [106] In December, Novartis announced it would purchase Gyroscope Therapeutics from health care investment company, Syncona Ltd, for up to $1.5 billion.

  • [55] Also in 2006, Sandoz became the first company to have a biosimilar drug approved in Europe with its recombinant human growth hormone drug.

  • [14] Novartis also has two significant license agreements with Genentech, a Roche subsidiary.

  • [69] In May 2014, Novartis purchased the rights to market Ophthotech’s Fovista (an anti-PDGF aptamer, also being investigated for use in combination with anti-VEGF treatments)
    outside the U.S. for up to $1 billion.

  • [58] In 2010, Novartis offered to pay US$39.3 billion to fully acquire Alcon, the world’s largest eye-care company, including a majority stake held by Nestlé.

  • [20] • Sandoz: As of 2013, Sandoz has been recognized as the world’s second-largest generic drug company.

  • [17] Place in its market segments Novartis is the world’s second-largest pharmaceutical company by market cap in 2019.

  • [94] In November 2019, Sandoz announced it would acquire the Japanese business of Aspen Global inc for €300 million (around $330 million), boosting the business’s presence
    in Asia.

  • [139] Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch.

  • [76] In June, the company announced it would acquire Spinifex Pharmaceuticals for more than $200 million.

  • [51][52] In 2003, Novartis organized all its generics businesses into one division, and merged some of its subsidiaries into one company, reusing the predecessor brand name
    of Sandoz.

  • [67] In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division.

  • [56] In 2007, Novartis sold the Gerber Products Company to Nestlé as part of its continuing effort to shed old Sandoz and Ciba-Geigy businesses and focus on healthcare.

  • [70] Novartis acquired exclusive rights to market the eye drug outside of the states while retaining U.S. marketing rights.

  • [107] In February 2022, New York City-based biotechnology company Cambrian Biopharma announced it had licensed rights to mTOR inhibitor programs from Novartis.

  • [85][86] In April of the same year, the business utilised some of the proceeds from the aforementioned GlaxoSmithKline deal to acquire Avexis for $218 per share or $8.7 billion
    in total, gaining the lead compound AVXS-101 used to treat spinal muscular atrophy.

  • [25][26] In 2018, Novartis sold its consumer healthcare joint venture vaccines division to GlaxoSmithKline for US$13.0 billion.

  • [140] When examination of Novartis’ patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling
    Gleevec in India and by advocacy groups.

  • Alcon was listed on the SIX exchange in Switzerland and NYSE exchange in the U.S.[20] Novartis announced during late 2019 a five-year artificial intelligence “alliance” with
    Microsoft.

  • [89] In mid-October, the company announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.

  • [59] Novartis created a new division and called it Alcon, under which it placed its CIBA VISION subsidiary and Novartis Ophthalmics, which became the second-largest division
    of Novartis.

  • [47] Post-merger[edit] Suffern, New York: one of the Novartis pharmaceutical production facilities in the United States Novartis India headquarters in HITEC City, Hyderabad
    In 1998, the company entered into a biotechnology licensing agreement with the University of California at Berkeley Department of Plant and Microbial Biology.

  • [62] In 2012, the Company cut ~2000 positions in the United States, primarily in sales, in response to anticipated revenue downturns from the hypertension drug Diovan, which
    was losing patent protection, and the realization that the anticipated successor to Diovan, Rasilez, was failing in clinical trials.

  • [61] 2011–present[edit] In 2011, Novartis acquired the medical laboratory diagnostics company Genoptix to “serve as a strong foundation for our (Novartis’) individualized
    treatment programs”.

  • [82] In December Novartis acquired Ziarco Group Limited, bolstering its presence in eczema treatments.

  • [27] • Consumer: Novartis is not a leader in the over-the-counter or animal health segments; its leading OTC brands are Excedrin and Theraflu, but sales have been slowed by
    problems at its key US manufacturing plant.

  • Multiple investigations by state and federal environmental and health agencies indicated that the likely source of the increased cancer risk was contamination from Toms River
    Chemical Plant (then operated by Ciba-Geigy), which had been in operation since 1952.

  • [137] Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India.

  • [16] The center supports the drug major’s operations in the pharmaceuticals (Novartis), eye care (Alcon) and generic drugs segments (Sandoz).

  • [1]It is one of the largest pharmaceutical companies in the world.

  • [93] On April 9, 2019, Novartis announced that it had completed the spin-off of Alcon as a separate commercial entity.

  • The company began producing the fever-reducing drug antipyrin in the same year.

  • [77] In August, the company acquired the remaining rights to the CD20 monoclonal antibody Ofatumumab from GlaxoSmithKline for up to $1 billion.

  • [98] In September 2020, Novartis was imposed a fine of €385 million by the French competition authority on accusations of abusive practices to preserve sales of Lucentis over
    a cheaper drug.

  • [46][47] Sandoz’s Master Builders Technologies, a producer of chemicals for the construction industry, was sold off to SKW Trostberg A.G., a subsidiary of the German energy
    company VIAG, while its North American corn herbicide business became part of the German chemical maker BASF.

  • [84] In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novartis to acquire Novartis’ 36.5 percent stake in their Consumer Healthcare Joint Venture
    for $13 billion (£9.2 billion).

  • [130] In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion
    (£9.2 billion).

  • [81] In December, the company acquired Encore Vision, gaining the company’s principle compound, EV06, is a first-in-class topical therapy for presbyopia.

  • [10] In August 2022, Novartis announced plans to spin off Sandoz as part of restructuring.

  • [96][97] In April 2020, the company announced it would acquire Amblyotech.

  • [66] In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards the company’s drugs.

  • [23] In August 2022, Novartis announced plans to spin off Sandoz by second half of 2023.

 

Works Cited

[‘https://www.novartis.com/research-development/research-locations
2. ^ “Novartis 1Q profit jumps 12 percent as heart drug sales soar”. Business. The Seattle Times. Associated Press. 19 April 2018. Archived from the original on 5 August 2020. Retrieved
20 April 2018.
3. ^ Jump up to:a b c d e f “Novartis Annual Report 2021” (PDF). Retrieved 4 February 2022.
4. ^ “The Pharmaceutical Industry in Figures – 2008 Edition”. European Federation of Pharmaceutical Industries and Associations (EFPIA).
p. 49. Archived from the original (PDF) on 16 September 2008. Retrieved 25 August 2008.
5. ^ “IFPMA Member List”. Archived from the original on 7 February 2014. Retrieved 29 January 2021.
6. ^ “404”. www.phrma.org. Archived from the original on
6 October 2013. Retrieved 29 January 2021. {{cite web}}: Cite uses generic title (help)
7. ^ “Share Ownership”. Novartis. 31 December 2019. Archived from the original on 27 January 2021. Retrieved 20 September 2020.
8. ^ Jump up to:a b “SEC 2010”.
Archived from the original on 6 August 2020. Retrieved 9 January 2020.
9. ^ Roland, Denise (17 May 2016). “Novartis Pharmaceuticals Head to Depart Amid Restructuring”. Wall Street Journal. Archived from the original on 5 August 2020. Retrieved 9
January 2020.
10. ^ “Alcon to Officially Spin out From Novartis on April 9”. BioSpace. Archived from the original on 6 August 2020. Retrieved 9 January 2020.
11. ^ Jump up to:a b c Mancini, Donato Paolo; Telling, Oliver (25 August 2022). “Novartis
to spin off generic drugs unit Sandoz”. Financial Times. Archived from the original on 10 December 2022.
12. ^ Jump up to:a b c “Novartis Annual Report 2012” (PDF). Novartis. Archived from the original (PDF) on 28 February 2013. Retrieved 6 February
2018.
13. ^ “Novartis to split Pharma business unit; names new CEOs”. www.thepharmaletter.com. Archived from the original on 13 August 2020. Retrieved 9 January 2020.
14. ^ “Novartis AG to Hold On to Its 33% Stake in Roche—For Now”. BioSpace.
Archived from the original on 1 November 2020. Retrieved 10 January 2020.
15. ^ “Avastin vs Lucentis” (PDF). Archived (PDF) from the original on 6 August 2020. Retrieved 29 January 2021.
16. ^ “Novartis slashing thousands more jobs in global reorganization,
shifting many to India”. FiercePharma. 2 February 2014. Archived from the original on 2 August 2019. Retrieved 4 February 2015.
17. ^ Datta, P. T. Jyothi (18 December 2015). “Novartis consolidates global services operations at Hyderabad centre”.
The Hindu BusinessLine. Archived from the original on 8 November 2020. Retrieved 6 February 2020.
18. ^ “Top 10 Pharma Companies of 2019”. 18 November 2019. Archived from the original on 11 November 2020. Retrieved 29 January 2021.
19. ^ “Novartis
Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal | GEN – Genetic Engineering and Biotechnology News”. GEN – Genetic Engineering and Biotechnology News. 15 December 2010. Archived from the original on 13 August 2020. Retrieved 14
January 2020.
20. ^ Jump up to:a b “Out From Under Novartis, Alcon Is Its Own Company Now”. BioSpace. Archived from the original on 23 September 2020. Retrieved 10 April 2019.
21. ^ Reuters, 21 October 2010 Biosimilars take off at Novartis generics
unit Archived 20 October 2013 at the Wayback Machine
22. ^ Staff, Generics and Biosimilars Initiative, 9 November 2012 Sandoz starts phase III US trial for biosimilar epoetin alfa Archived 20 October 2013 at the Wayback Machine
23. ^ “20-F”. www.sec.gov.
p. 63. Archived from the original on 5 August 2020. Retrieved 11 March 2019.
24. ^ Morse, Andrew (11 November 2013). “Novartis Sells Unit for $1.68 Billion”. Wall Street Journal. ISSN 0099-9660. Archived from the original on 5 August 2020. Retrieved
21 January 2020.
25. ^ “CSL completes Novartis influenza vaccine acquisition in Germany”. www.seqirus.com. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
26. ^ “GSK Pharma completes acquisition of Novartis Healthcare’s
vaccines business”. 30 September 2015. Archived from the original on 5 January 2021. Retrieved 21 January 2020.
27. ^ “Glaxo (GSK) Buys Novartis’ Stake in Consumer Healthcare JV”. finance.yahoo.com. Archived from the original on 5 August 2020.
Retrieved 11 March 2019.
28. ^ Staff and wire reports for the Journal Star (LIncoln, Nebraska) 14 August 2013 Novartis reviews business; analyst urges selling OTC unit Archived 24 April 2019 at the Wayback Machine
29. ^ Staff, WHO. Access to Medicine
Index, 2012
30. ^ “Novartis AG”. Access to Medicine Foundation. Archived from the original on 30 January 2021. Retrieved 22 November 2019.
31. ^ McNeil, Donald G. Jr. (28 June 2010). “The Drug Industry: GlaxoSmithKline, Merck and Novartis Again
Rank Highest on Access to Poor”. The New York Times. ISSN 0362-4331. Archived from the original on 10 September 2020. Retrieved 21 January 2020.
32. ^ “Novartis AG Revenue 2006-2018 | NVS”. www.macrotrends.net. Archived from the original on 11 November
2020. Retrieved 11 March 2019.
33. ^ Jump up to:a b “A history of Novartis -“. pharmaphorum.com. 20 September 2013. Archived from the original on 2 December 2020. Retrieved 21 January 2020.
34. ^ “Novartis AG | Swiss company”. Encyclopedia Britannica.
Archived from the original on 27 October 2020. Retrieved 21 January 2020.
35. ^ “J R Geigy SA | Science Museum Group Collection”. collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.
36. ^
“J. R. Geigy Soc. An. | Science Museum Group Collection”. collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.
37. ^ “Ciba-Geigy AG | Swiss pharmaceutical company”. Encyclopedia Britannica.
Archived from the original on 10 October 2017. Retrieved 21 January 2020.
38. ^ “Company history”. Novartis.com. 15 December 2010. Archived from the original on 30 December 2010. Retrieved 2012-01-16.
39. ^ “Albert Hofmann, 102, Invented LSD –
The New York Sun”. Nysun.com. Archived from the original on 20 October 2013. Retrieved 23 October 2013.
40. ^ “Patent US2438259 – D-lysergic acid diethyl amide”. google.com. Archived from the original on 9 June 2016. Retrieved 11 November 2016.
41. ^
“Albert Hofmann: LSD – My Problem Child: Use of LSD in Psychiatry”. Flashback.se. Archived from the original on 7 July 2006. Retrieved 16 January 2012.
42. ^ “Medicine: Dream Stuff”. Time. 28 June 1954. Archived from the original on 27 August 2013.
43. ^
“CIA considered big LSD purchase”. The New York Times. 5 August 1976. Retrieved 25 May 2022.
44. ^ Anna Bálint: Clariant clareant. The beginnings of a specialty chemicals company, Campus Verlag, Frankfurt am Main/New York 2012, ISBN 978-3-593-39374-2.
45. ^
Magnus Grimond for The Independent. 8 March 1996 Ciba-Geigy and Sandoz to merge into pounds 40bn giant Archived 14 December 2013 at the Wayback Machine
46. ^ Jump up to:a b Glenn Collins for The New York Times. 7 March 1996 2 Swiss Drug Giants In
a Surprise Merger To Be 2d in World Archived 8 December 2020 at the Wayback Machine
47. ^ Jump up to:a b Lawrence M. Fisher for strategy + business. 1 April 1998 Post-Merger Integration: How Novartis Became No. 1 Archived 20 May 2013 at the Wayback
Machine
48. ^ Macilwain, Colin (1 November 1998). “Berkeley teams up with Novartis in $50m plant genomics deal”. Nature. 396 (6706): 5. Bibcode:1998Natur.396….5M. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
49. ^ Dalton, Rex (1 May 1999).
“Berkeley dispute festers over biotech deal”. Nature. 399 (6731): 5. Bibcode:1999Natur.399….5D. doi:10.1038/19807. ISSN 1476-4687. PMID 10331373.
50. ^ Dalton, Rex (1 November 2003). “Syngenta ends plant-research deal with Berkeley”. Nature. 426
(6964): 216. Bibcode:2003Natur.426..216D. doi:10.1038/426216a. ISSN 1476-4687. PMID 14628007.
51. ^ Andrew Ross Sorkin for The New York Times. 3 December 1999 AstraZeneca and Novartis To Shed Agricultural Units Archived 11 September 2020 at the
Wayback Machine Accessed 27 May 2013
52. ^ Staff, PRNewsWire. 13 November 2000. Syngenta Begins Trading on the New York Stock Exchange Accessed 27 May 2013[dead link]
53. ^ Press Release, Novartis. 21 January 2003 Novartis to Unite Its Generics
Businesses Under One Single Global Brand: Sandoz Archived 17 October 2013 at the Wayback Machine
54. ^ Emily Church for MarketWatch 21 February 2005 Novartis in $8.29 billion generics deals: to buy Hexal and its US division Eon Labs Archived 20
October 2013 at the Wayback Machine
55. ^ Novartis press release. 19 April 2006 Novartis acquisition of Chiron approved by Chiron shareholders Archived 20 October 2013 at the Wayback Machine
56. ^ Staff, Biosimilars News. 15 August 2011 Biosimilars
approved in Europe Archived 20 October 2013 at the Wayback Machine
57. ^ Andrew Martin and Andrew Ross Sorkin for The New York Times. 13 April 2007 Nestlé Agrees to Buy Gerber From Novartis Archived 23 November 2020 at the Wayback Machine
58. ^
“Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL®”. www.worldpharmanews.com. Archived from the original on 13 November 2009. Retrieved 29 January 2021.
59. ^ Thomasson, Emma (4 January 2010). “Novartis
seeks to buy rest of Alcon for $39 billion”. Reuters. Archived from the original on 20 October 2013. Retrieved 4 January 2010.
60. ^ Novartis Press Release. 8 April 2011 Stronger together: Novartis and Alcon creating the global leader in eye care
Archived 20 October 2013 at the Wayback Machine
61. ^ “Can Novartis’ CEO resist going for a megamerger with cash from asset sales? – FiercePharma”. www.fiercepharma.com. 30 May 2017. Archived from the original on 30 October 2020. Retrieved 6 February
2018.
62. ^ Maclucas, Neil (24 January 2011). “Novartis to Buy Genoptix for $470 Million”. Health. The Wall Street Journal. Archived from the original on 10 January 2014.
63. ^ “Novartis to cut almost 2,000 US jobs this year”, The Jakarta Post,
Associated Press, jakartapost.com, 13 January 2012, archived from the original on 25 May 2013, retrieved 2012-01-15
64. ^ Reid, Katie (13 January 2012), Hans-Juergen Peters and Mike Nesbit (ed.), Novartis cuts 2,000 U.S. jobs after drug setback,
Reuters, reuters.com, archived from the original on 10 January 2014, retrieved 2012-01-15
65. ^ De la Merced, Michael J. (2 May 2012). “Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion”. DealB%k. The New York Times. Archived from the original
on 5 August 2020. Retrieved 25 January 2020.
66. ^ Jump up to:a b c Harris, Gardiner; Thomas, Katie (1 April 2013). “Top Court in India Rejects Novartis Drug Patent”. The New York Times. Archived from the original on 30 May 2020. Retrieved 1 April
2013.
67. ^ “US sues Novartis again, says it bribed doctors for patents”. Indian Express. Associated Press. Archived from the original on 1 June 2013. Retrieved 29 April 2013. Note: Link provides access to first of two pages; second page is here
Archived 23 April 2020 at the Wayback Machine.
68. ^ Staton, Tracy (21 January 2014). “Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics”. FiercePharma. Questex. Archived from the original on 26 March 2014. Retrieved 19 February
2014.
69. ^ Johnson, Michael (18 January 2014). “Novartis acquires CoStim Pharmaceuticals”. Drug Store News. Lebhar-Friedman. Archived from the original on 25 February 2014. Retrieved 19 February 2014.
70. ^ Jump up to:a b c “Novartis Buys Ex-U.S.
Rights to Ophthotech’s Fovista for Up to $1B”. News | Industry Watch. Genetic Engineering & Biotechnology News (Paper). Vol. 34, no. 12. Mary Ann Liebert. 15 June 2014. p. 8. Archived from the original on 5 August 2020. Retrieved 25 January 2020.
71. ^
“Ophthotech Pockets $50M Milestone from Novartis for AMD Treatment”. GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 8 September 2014. Archived from the original on 11 May 2018. Retrieved 14 September 2014.
72. ^
BBC (22 April 2014). “Novartis and GSK exchange assets”. BBC. Archived from the original on 29 April 2014. Retrieved 22 April 2014.
73. ^ “Novartis Takes Stake in Gamida with Option to Fully Buy”. Genetic Engineering & Biotechnology News. Mary Ann
Liebert. 19 August 2014. Archived from the original on 11 May 2018. Retrieved 25 January 2020.
74. ^ “Novartis Selling Flu Vaccine Business to CSL for $275M”. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 27 October 2014. Archived
from the original on 3 September 2018. Retrieved 25 January 2020.
75. ^ “Array BioPharma Completes Deal with Novartis for 2 Cancer Compounds”. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 2 March 2015. Archived from the original on
2 July 2017. Retrieved 25 January 2020.
76. ^ “Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement”. GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 5 March 2015. Archived from the original on 9 April
2015. Retrieved 8 June 2016. Note: appears on page 10 of 1 April 2015 print issue.
77. ^ “Novartis Acquires Spinifex for $200M+”. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 29 June 2015. Archived from the original on 4 March 2016.
Retrieved 25 January 2020.
78. ^ Helfand, Cindy (21 August 2015). “Novartis shells out up to $1B to test GSK’s Arzerra in MS”. FiercePharma. Questex. Archived from the original on 4 April 2016. Retrieved 25 January 2020.
79. ^ “Novartis Acquires
All Remaining Rights to GSK’s Ofatumumab”. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 August 2015. Archived from the original on 23 August 2015.
80. ^ “Novartis Buys Admune; Licenses Palobiofarma, XOMA Compounds”. Genetic Engineering
& Biotechnology News. Mary Ann Liebert. 21 October 2015. Archived from the original on 17 August 2017. Retrieved 25 January 2020.
81. ^ “Novartis Acquires Selexys Pharmaceuticals – GEN Genetic Engineering & Biotechnology News – Biotech from Bench
to Business – GEN”. 21 November 2016. Archived from the original on 30 October 2018. Retrieved 21 November 2016.
82. ^ “Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops – GEN Genetic Engineering & Biotechnology News – Biotech from Bench
to Business – GEN”. 20 December 2016. Archived from the original on 21 December 2016. Retrieved 21 December 2016.
83. ^ Terry, Mark (19 December 2016). “Novartis AG Snaps Up Mid-Stage Eczema Rival”. BioSpace. Archived from the original on 6 August
2020. Retrieved 29 October 2018.
84. ^ Reuters Editorial (3 November 2017). “Novartis to buy French cancer specialist AAA for $3.9 billion”. Reuters. Archived from the original on 17 November 2018. Retrieved 6 February 2018. {{cite news}}: |author=
has generic name (help)
85. ^ “GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business | GSK”. www.gsk.com. 27 March 2018. Archived from the original on 27 November 2020. Retrieved 27 March 2018.
86. ^ Jump
up to:a b “GSK buys out Novartis in $13 billion consumer healthcare shake-up”. Reuters. 27 March 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
87. ^ “Novartis bets big on gene therapy with $8.7 billion AveXis deal”.
Reuters. 9 April 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
88. ^ “Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech | FierceBiotech”. www.fiercebiotech.com. August 2018. Archived from
the original on 5 August 2020. Retrieved 3 August 2018.
89. ^ “China’s Laekna Inks Two-Drug Deal with Novartis | BioSpace”. BioSpace. Archived from the original on 5 August 2020. Retrieved 3 August 2018.
90. ^ “Novartis to buy cancer drugmaker
Endocyte for $2.1 billion in cash”. Reuters. 18 October 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
91. ^ “Novartis pushes deeper into nuclear medicine with $2.1 billion deal”. Reuters. 18 October 2018. Archived
from the original on 5 August 2020. Retrieved 9 January 2019.
92. ^ “Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms”. Novartis. 18
October 2018. Archived from the original on 25 November 2020. Retrieved 18 October 2018.
93. ^ “Novartis to buy France’s CellforCure to boost cell, gene therapy”. Reuters. 20 December 2018. Archived from the original on 6 August 2020. Retrieved
20 December 2018.
94. ^ Neville, Sarah; Waters, Richard (October 2019). “Novartis and Microsoft join forces to develop drugs using AI”. Financial Times. Archived from the original on 4 October 2020. Retrieved 5 November 2019.
95. ^ “Sandoz Boosts
Toehold in Japan with Aspen Acquisition”. BioSpace. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
96. ^ Terry, Mark (25 November 2019). “Novartis Buys The Medicines Company: A $9.7 Billion Gamble on a PCSK9 Cholesterol Drug”.
BioSpace. Urbandale, Iowa. Archived from the original on 6 August 2020. Retrieved 1 December 2019.
97. ^ “Novartis set to buy Medicines Co. for $9.7 billion”. Leaders League. Paris. 26 November 2019. Archived from the original on 5 August 2020.
Retrieved 1 December 2019.
98. ^ “Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis”. BioSpace. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
99. ^ “Pharmaceutical giants fined record €444
million for ‘abusive practices'”. The Brussels Times. 9 September 2020. Archived from the original on 9 October 2020. Retrieved 13 September 2020.
100. ^ “BuyNTech buys Novartis site to boost EU vaccine production”. Financial Times. 17 September
2020. Archived from the original on 15 January 2021. Retrieved 21 September 2020.
101. ^ “Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company”. BioSpace. Archived from the original on 7 November 2020. Retrieved 29 January
2021.
102. ^ “Novartis Expands Footprint in Gene and Cell Therapy with Vedere Bio Acquisition”. BioSpace. Archived from the original on 25 November 2020. Retrieved 29 January 2021.
103. ^ Global Legal Chronicle Archived 11 November 2020 at the
Wayback Machine Molecular Partners Option and License Agreement with Novartis (30 October 2020)
104. ^ “Cadent Therapeutics Enters Agreement to be Acquired by Novartis”. BioSpace. Archived from the original on 5 February 2021. Retrieved 29 January
2021.
105. ^ Reuters Staff (17 December 2020). “Novartis buys neuroscience company Cadent for up to $770 million”. Reuters. Archived from the original on 4 February 2021. Retrieved 29 January 2021 – via www.reuters.com. {{cite news}}: |author= has
generic name (help)
106. ^ “Novartis Adds to Optogenetics Portfolio with Arctos Medical Buy”. Archived from the original on 23 September 2021. Retrieved 23 September 2021.
107. ^ Mitra, Sinchita (22 December 2021). “Novartis buys Gyroscope for
$1.5 BLN to add new retinal gene therapy”. Reuters. Archived from the original on 23 December 2021. Retrieved 23 December 2021.
108. ^ Jump up to:a b “Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer”.
Endpoints. 16 February 2022. Retrieved 14 March 2022.
109. ^ Kresge, Naomi (25 August 2022). “Novartis to Spin Off Sandoz Generic Drug Unit by Next Year”. Bloomberg News. Archived from the original on 25 August 2022.
110. ^ Ross, Casey (27 October
2010). “Novartis doubles plan for Cambridge”. The Boston Globe. Archived from the original on 3 November 2012. Retrieved 31 October 2010.
111. ^ “Novartis Institutes for BioMedical Research”. Novartis. Archived from the original on 2 May 2014. Retrieved
29 January 2021.
112. ^ “Innovation for the developing world”. Archived from the original on 9 February 2014. Retrieved 29 January 2021.
113. ^ Mattes, William B. (2008). “Public Consortium Efforts in Toxicogenomics”. In Mendrick, Donna L.; Mattes,
William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
114. ^ InnoMed PredTox Member Organizations (web page), InnoMed,
archived from the original on 26 September 2008, retrieved 25 August 2008
115. ^ Innovative Medicines Initiative, ed. (2008), “IMI-GB-018v2-24042008-CallTopics.pdf”, IMI 1st Call 2008: Information Package (ZIP archive), European Commission, archived
from the original (PDF) on 24 September 2015, retrieved 16 January 2012
116. ^ “Novartis, U.S. partner plan remote trials to boost participation”. Reuters. 7 March 2018. Archived from the original on 9 November 2020. Retrieved 15 March 2018.
117. ^
Jump up to:a b c d e f g h i j k l m n o p q r s t Novartis Top 20 Products Annual Sales (Novartis Website), accessed 19 October 2013 Archived 28 April 2014 at the Wayback Machine
118. ^ Teva press release. 30 January 2007 Teva Receives Approval
for Generic Focalin™ Tablets Archived 13 August 2020 at the Wayback Machine
119. ^ “IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI”. Archived from the original on 20 October 2013.
120. ^
Jump up to:a b c Novartis official 2007 product sales From Internet Archive; archive date 13 November 2007
121. ^ Commissioner, Office of the (11 September 2019). “FDA approves new oral drug to treat multiple sclerosis”. FDA. Archived from the original
on 9 February 2021. Retrieved 16 October 2019.
122. ^ “Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease”. Novartis. Archived from the original on 20 November 2020.
Retrieved 16 October 2019.
123. ^ “Sertraline Sandoz Tablet”. NPS MedicineWise. Archived from the original on 9 January 2019. Retrieved 9 January 2019.
124. ^ “EU/3/09/671 | European Medicines Agency”. Archived from the original on 4 February
2014. Retrieved 29 January 2021.
125. ^ “FDA Approves Pasireotide for Cushing’s Disease”. Archived from the original on 30 July 2013.
126. ^ Jump up to:a b “NICE Backs Novartis’s Tasigna For CML, Rejects BMS’s Sprycel”, The Wall Street Journal,
online.wsj.com, 12 January 2012, archived from the original on 17 May 2013, retrieved 2012-01-15
127. ^ Jump up to:a b Teva press release. 14 October 2013 Teva Announces FDA Approval of Generic TOBI® in the United States[permanent dead link]
128. ^
Jump up to:a b Teva Press Release 12 December 2007 Teva Announces Approval of Generic Trileptal Tablets Archived 20 October 2013 at the Wayback Machine
129. ^ “US Department of Health and Human Services awards Novartis USD 486 million contract to
build manufacturing facility for pandemic flu vaccine” (Press release). Novartis. 15 January 2009. Archived from the original on 3 June 2010. Retrieved 13 November 2009.
130. ^ Staton, Tracy (22 April 2014). “Novartis, GSK team up in consumer JV
to save big money, gain big scale”. FiercePharma. Questex Media Group. Archived from the original on 26 October 2020. Retrieved 16 May 2016.
131. ^ Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However,
according to the decision of the IPAB on 26 June 2009 (page 27) discussed below, “The Appellant’s application under the PCT was substantially on the same invention as had been made in India.” Archived 22 October 2013 at the Wayback Machine
132. ^
“Crystal Modification of a N-Phenyl-2-Pyrimidineamine Derivative, Processes for Its Manufacture and Its Use”. Archived from the original on 22 October 2013. Retrieved 29 January 2021.
133. ^ Staff, European Medicines Agency, 2004. EMEA Scientific
Discussion of Glivec Archived 20 September 2018 at the Wayback Machine
134. ^ “Patent US5521184 – Pyrimidine derivatives and processes for the preparation thereof”. google.com. Archived from the original on 15 December 2020. Retrieved 11 November
2016.
135. ^ “Espacenet – results view”. worldwide.espacenet.com. Archived from the original on 17 November 2018. Retrieved 29 January 2021.
136. ^ Indian Supreme Court Decision paragraphs 5-6 Archived 6 July 2013 at the Wayback Machine
137. ^
“Novartis v UoI, para 8-9”. Archived from the original on 6 July 2013. Retrieved 29 January 2021.
138. ^ Jump up to:a b Shamnad Basheer for Spicy IP 11 March 2006 First Mailbox Opposition (Gleevec) Decided in India Archived 21 October 2013 at the
Wayback Machine
139. ^ Staff, LawyersCollective. 6 September 2011 Novartis case: background and update – Supreme Court of India to recommence hearing Archived 21 October 2013 at the Wayback Machine
140. ^ Jump up to:a b R. Jai Krishna and Jeanne
Whalen for The Wall Street Journal. 1 April 2013 Novartis Loses Glivec Patent Battle in India Archived 26 October 2014 at the Wayback Machine
141. ^ “IPAB Order Dated 26-Jun-2009 in Novartis v. Union of India | Patent Application | Patent”. Scribd.
Archived from the original on 22 October 2013. Retrieved 29 January 2021.
142. ^ “W.P. No.24759 of 2006”. Archived from the original on 20 October 2013. Retrieved 29 January 2021.
143. ^ “Supreme Court rejects bid by Novartis to patent Glivec”.
Archived from the original on 17 December 2013.
144. ^ “Novartis v UoI, Para 191”. Archived from the original on 6 July 2013. Retrieved 29 January 2021.
145. ^ “Novartis v UoI, Para 24-25”. Archived from the original on 6 July 2013. Retrieved
29 January 2021.
146. ^ “How the Indian judgment will reverberate across the world”. Archived from the original on 18 January 2014.
147. ^ “Patented drugs must be priced smartly”. Archived from the original on 20 October 2013.
148. ^ “Patent
with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013”. Archived from the original on 26 May 2013. Retrieved 29 January 2021.
149. ^ Kevin Grogan for PharmaTimes. 27 February 2012 Novartis explains stance over India patent law challenge
Archived 16 December 2014 at the Wayback Machine
150. ^ Erklärung von Bern. 8 May 2007 Short questions and answers about the court case initiated by Novartis in India Archived 21 October 2013 at the Wayback Machine
151. ^ “Shift in Novartis Strategy,
The Telegraph”. Archived from the original on 11 May 2013. Retrieved 29 January 2021.
152. ^ Voris, Bob Van (14 July 2010). “Novartis Reaches $152.5 Million Sex-Bias Settlement”. Archived from the original on 18 May 2018. Retrieved 29 January 2021
– via www.washingtonpost.com.
153. ^ “Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII”. Warning Letters. US Food and Drug Administration. 25 September 2008. Archived from the original on 10 February 2012. Retrieved 2009-08-05.
154. ^
Jump up to:a b Wilson, Duff (30 September 2010). “Novartis Settles Off-Label Marketing Case”. The New York Times. Archived from the original on 16 November 2018. Retrieved 16 January 2012.
155. ^ “Novartis Pharmaceuticals Corporation, a US subsidiary
of Novartis AG, reaches settlement agreement with US Attorney’s Office” (press release). Novartis. 30 September 2010. Media Releases. Archived from the original on 17 October 2013. Retrieved 16 January 2012.
156. ^ Jump up to:a b c “U.S. Sues Novartis
Again, Accusing It of Kickbacks”. The New York Times. 26 April 2013. Archived from the original on 5 October 2019. Retrieved 27 April 2013.
157. ^ Jump up to:a b “United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly
Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs”. The United States Department of Justice. 26 April 2013. Archived from the original on 13 April 2014. Retrieved 26 April 2013.
158. ^ Andrew Pollack for The New York Times. 28 April
2011 Cheaper Drug to Treat Eye Disease Is Effective Archived 16 September 2018 at the Wayback Machine
159. ^ Jump up to:a b Jeffreys, Branwen (6 May 2012). “Using Avastin for eye condition wet AMD ‘could save NHS £84m'”. bbc.com. Archived from
the original on 6 November 2013. Retrieved 6 May 2012.
160. ^ Copley, Caroline; Hirschler, Ben (24 April 2012), Potter, Mark (ed.), Novartis challenges UK Avastin use in eye disease, Reuters, archived from the original on 22 May 2013, retrieved
2012-04-29
161. ^ Ben Adams for Pharmafile. 26 July 2012 Lucentis price cut ends PCT-Novartis dispute Archived 19 October 2013 at the Wayback Machine
162. ^ Ben Adams for Pharma Times. 3 October 2012. Novartis to drop legal case against NHS body
Archived 19 October 2013 at the Wayback Machine
163. ^ Jump up to:a b Kana Inagaki for The Wall Street Journal. 11 August 2013 Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart
Medicine Diovan Archived 13 October 2013 at the Wayback Machine
164. ^ Kana Inagaki for The Wall Street Journal. 12 August 2013. Novartis Drug Studies in Japan–Tracing Back the Questions Archived 18 October 2013 at the Wayback Machine
165. ^ “Japan
Criminal Probe Could Spell More Trouble for Novartis”. The Wall Street Journal. 10 January 2014. Archived from the original on 2 March 2014.
166. ^ “Data manipulation by staff gets Novartis into legal mess in Japan”. Japan Herald. Archived from
the original on 29 August 2014. Retrieved 2 July 2014.
167. ^ Jump up to:a b “Greek Officials Hit Back at Novartis Bribery Allegations | GreekReporter.com”. greece.greekreporter.com. 6 February 2018. Archived from the original on 1 November 2020.
Retrieved 7 February 2018.
168. ^ “Greek officials ban Novartis manager from leaving the country amid widening bribery probe: report | FiercePharma”. www.fiercepharma.com. Archived from the original on 9 November 2020. Retrieved 7 February 2018.
169. ^
“Greek Govt Alleges Official Ties to Drug Bribery Scandal”. The New York Times. Associated Press. 5 February 2018. ISSN 0362-4331. Archived from the original on 16 November 2018. Retrieved 7 February 2018.
170. ^ “Ν. Ηλιόπουλος: Και με τη βούλα
της Δικαιοσύνης υπαρκτό το σκάνδαλο Novartis”. capital.gr. Retrieved 27 July 2022.
171. ^ (http://www.dw.com), Deutsche Welle. “Novartis under investigation for bribery in Greece | Europe| News and current affairs from around the continent | DW
| 22.01.2017”. DW.COM. Archived from the original on 12 November 2020. Retrieved 7 February 2018.
172. ^ “SEC.gov | SEC Charges Novartis AG with FCPA Violations”. www.sec.gov. Archived from the original on 18 January 2021. Retrieved 25 June 2020.
173. ^
“Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases”. www.justice.gov. 25 June 2020. Archived from the original on 13 January 2021. Retrieved 25 June 2020.
174. ^ “Novartis admits $1.2m
in payments to Trump lawyer”. Financial Times. Archived from the original on 9 November 2020. Retrieved 10 May 2018.
175. ^ Emma Court (16 July 2018.) Novartis had ‘longer and more detailed’ relationship with Trump lawyer Michael Cohen, Senate
report finds Archived 15 November 2020 at the Wayback Machine. MarketWatch. Retrieved 21 August 2018.
176. ^ White House Access for Sale: Michael Cohen, Novartis and the bid to sell access to the Trump administration Archived 13 November 2020 at
the Wayback Machine. Retrieved 21 August 2018.
177. ^ “Leprosy”. www.who.int. Archived from the original on 31 January 2021. Retrieved 19 January 2021.
178. ^ “WHO | WHO and Novartis extend agreement to treat millions of leprosy patients with
free medicines”. WHO. Archived from the original on 19 October 2015. Retrieved 19 January 2021.
179. ^ “WHO | New Memorandum of Understanding for MDT”. WHO. Archived from the original on 11 October 2014. Retrieved 19 January 2021.
Photo credit:
https://www.flickr.com/photos/51456203@N00/898102603/’]